Moving CAR T-cell therapy to earlier treatment lines is crucial. This approach targets cancer before it develops resistance and, more importantly, utilizes patient T-cells that are healthier and more effective, not having been damaged by extensive prior chemotherapy regimens.

In follicular lymphoma, the treatment goal is durable remission with manageable toxicity, not necessarily a cure. Therefore, clinicians frequently prefer using a bispecific antibody first, reserving the more complex and toxic CAR-T cell therapy for transformed disease or after a bispecific fails.

The efficacy of Siltacel stems from a powerful initial expansion that eliminates cancer upfront. The CAR-T cells are often undetectable beyond six months, indicating their curative potential comes from an overwhelming initial response rather than persistent, long-term immune policing of the disease.

As CAR-T cell therapies are increasingly adopted for second-line treatment of large cell lymphoma, epcoritamab is solidifying its role as a critical, potentially curative replacement option in the third-line setting. This establishes a clear sequential treatment pathway for patients who continue to relapse.

Using a BCMA bispecific antibody first can exhaust a patient's T-cells or cause tumors to lose the BCMA target, rendering a subsequent BCMA-targeted CAR-T therapy ineffective. The optimal sequence is CAR-T first, which preserves T-cell function and BCMA expression, leaving bispecifics as a viable later-line option.

Experts report successfully treating lymphoma patients as old as 92 with CAR-T, even those with mild cognitive impairment. This demonstrates that chronological age alone is not an absolute contraindication; functional status is a more critical determinant of eligibility for intensive therapies.

Contrary to typical findings where real-world data underperforms, liso-cel CAR T-cell therapy in CLL demonstrates significantly better outcomes in practice than in its approval trial (over 80% response rate vs. under 50%). This suggests that using the therapy earlier in healthier, less-refractory patients unlocks its true potential.

The next major shift for CAR T-cell therapy is its integration into frontline treatment. Instead of being reserved for relapse, it's being tested as a consolidation therapy that could replace the standard two to three years of maintenance chemotherapy, dramatically shortening treatment duration.

Current CAR-T therapy for CLL requires a complete response (CR) for long-term benefit. A partial response provides only about two years of disease control, an outcome similar to the oral drug pirtobrutinib but with significantly more toxicity, complexity, and logistical burden for the patient.